La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Chugai Pharmaceutical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Chugai Pharmaceutical..

Chugai Pharmaceutical (OTC:CHGCY) Azioni, Catena delle Opzioni

CHUGAI PHARMACEUTICA

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and Actemra for treating rheumatoid arthritis and covid patients.

Weight Loss Drugs

Biotech

News

Health Care

General

CHGCY

RHHBY

Un farmaco nato per un altro scopo potrebbe risolvere il più grande effetto collaterale delle nuove terapie dimagranti.

Perdere peso senza perdere muscoli: la scommessa di Eli Lilly

CHUGAI PHARM UNSP/ADR by Chugai Pharmaceutical Co., Ltd.

Comments

Chugai Pharmaceutical

Chugai Pharmaceutical (CHGCY) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO